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ABSTRACT 
Objective: To increase the solubility/dissolution of benznidazole (BNZ) in water using two systems: solid dispersions (SD) with 
hydroxypropylmethylcellulose (HPMC) and β-cyclodextrin (β-CD) inclusion complexes (IC).  
Methods: The samples were obtained by physical mixtures (PM), kneading (KN), evaporation (EV) and by spray-dryer (SY) atomization The 
analysis was based on results of in vitro dissolution and molecular modeling techniques.  
Results: Molecular modeling showed that BNZ can form β-CD complexes in different ways such as in an aqueous solution or a vacuum. In vitro dissolution 
showed significant improvement in BNZ solubility in the PM, SD and IC, and also that the β-CD IC promoted better solubility than SD with HPMC.  
Conclusion: Considering the data obtained, it is possible to consider the technique for the formation of β-CD IC as a more effective technique in 
promoting the improvement of BNZ solubility compared with getting SD with HPMC which, in turn, may increase the bioavailability of the drug and 
improve their pharmaceutical potential. 
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INTRODUCTION 
Each drug has a different profile and a unique delivery and action in 
specific targets. This profile refers to its solubility in water. Poorly 
soluble drugs in aqueous solutions have low bioavailability when 
administered orally. This fact can be attributed to three factors: the 
possible degradation of the drug in the digestive tract, the low 
dissolution rate and low permeability of the drug through the walls 
of the digestive apparatus [1]. Promoting an increased 
solubility/dissolution rate of drugs with these characteristics is one 
of the most important stages in the development of its 
pharmaceutical form [2]. 
BNZ, N-benzil-2-nitro-1-imidazolacetamide, is the drug of choice for 
treatment of Chagas disease [3], which is itself as an endemic disease 
in many Latin American countries and affects 16-18 million people in 
the world [4]. BNZ therapy is effective in the onset of the acute and 
chronic disease, presenting, as main problems, low solubility and high 
toxicity of this drug. Low water solubility leads, consequently, to the 
limitations in bioavailability. Therefore, in order to improve poor drug 
solubility/dissolution in water, several techniques have been used, 
including solid dispersions (SD) with hydrophilic polymers and 
cyclodextrins (CD) inclusion complexes (IC) [5]. 
SD systems can increase the dissolution rate and bioavailability of 
water-insoluble drugs, once these are exposed to an aqueous 
medium as the carrier which dissolves and releases the drug as very 
fine colloidal particles. This greatly reduces particle size and 
increases the surface area resulting in improved dissolution and oral 
absorption rates. Furthermore, no energy is required to break up the 
crystal lattice of a drug during the dissolution process. Drug 
solubility and wettability may be increased by surrounding 
hydrophilic carriers [6]. Several highly soluble substances can be use 
to accelerate the release of poor hydrosoluble drugs [7]. 
CDs are cyclic oligosaccharides consisting of six, seven and eight 
glucose units called α, β and γ-cyclodextrins, respectively, and are 
linked by α-1,4 molecules [8]. These compounds are able to form 
inclusion complexes with a large variety of organic compounds by 
replacing the water molecules, which have high enthalpy by 
appropriate guest molecules. The CD functions as molecular carriers 
carrying the hydrophobic guest molecules in solution to the 
lipophilic cell membranes which, with a higher affinity, aid their 
uptake [9]. 
β-CD (fig. 1A) is the most used natural cyclodextrin. It offers a low 
cost and the duration of the patent has expired. Also, its cavity size is 
suitable to include aromatic and heterocyclic rings [10-12]. 
Likewise, hydrophilic polymers, such as HPMC (fig. 1B), have been 
used in solid dispersion systems. Thus, the solubilizing effect of CD 
may also be enhanced by the use of these polymers [13]. 
This study aims to assess the increment of BNZ 
solubility/dissolution in binary systems involving SD with HPMC 
and β-CD IC. Thus, a physical mixture (PM) and other different 
techniques of production can be used: kneading (KN), evaporation 
(EV) and spray-dryer atomization (SY) and detailed study of 
molecular modeling to evaluate the complexation of BNZ with β-CD. 
 
 
Fig. 1: Chemical structure of β-cyclodextrin (A) and 
Hydroxypropylmetylcellulose (B) 
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MATERIALS AND METHODS 
Material 
Benznidazole (BNZ), reference substance (99.9%), manufactured by 
Roche® was supplied by the Pharmaceutical Laboratory of the State 
of Pernambuco (LAFEPE®); Hydroxypropylmetylcellulose (HPMC) 
was supplied by Dow®; β-cyclodextrin (β-CD) was supplied by Apsen 
Phamraceutics®; etanol, was supplied by Vetec®, and pure water was 
obtained by a reverse osmosis system (Gehaka® 20) with an 
attached Gehaka®. deionizer  
BNZ assay 
The assay was performed according to a methodology developed 
and validated by Soares-Sobrinho et al. (2006) [14], using a UV-
visible spectrophotometer at a wavelengh of 324 nm. 
Preparation of samples 
Preparation of physical mixtures 
Initially, the BNZ PM and HPMC were precisely weighed at a ratio of 
1:1 (w/w) and the BNZ PM and β-CD were mixed at a ratio of 1:1 
(molar ratio). Each of these were pulverized in a porcelain mortar 
with the aid of a pestle until a homogeneous mixture of powders was 
obtained. The mixtures were then shifted into 250 μm meshes, 
transferred to suitable containers and kept in a desiccator. The PMs 
obtained were called a HPMC PM and a β-CD PM. 
Preparation of solid dispersion and inclusion complexes 
Evaporated 
A SD of BNZ with HPMC (1:1, w/w) and a BNZ IC with β-CD (1:1, molar 
ratio) were prepared by the solvent evaporation method. Each 
compound was separately dissolved using ethanol and water (2:1) as 
solvents at a minimum ratio necessary to solubilize them. The solvents 
were removed by a MA 120 Marconi® rotary evaporator at a fixed 
temperature (60 ºC), reduced pressure (-800 mbar) and a rotation of 
130 rpms. After spending 12 h in a desiccator, samples were 
pulverized in a mortar with a pestle and sieved with the aid of a 250 
μm mesh. The SD and the resulting IC were transferred to appropriate 
containers, protected from light and kept in a desiccator for further 
characterization. The samples were named HPMC EV and β-CD EV. 
Kneaded 
Samples were precisely weighed in the same proportions and sprayed 
earlier in a porcelain mortar with the aid of a pestle, with simultaneous 
wetting of the powder with a ethanol/water solution at a ratio of 2:1 
(V/V) until a homogeneous mixture was obtained. Samples were dried at 
60 °C for 14 h for the removal of the ethanol/water solution. The 
resulting samples were sieved in a mesh of 250 μm and transferred to 
suitable containers for future characterizations. The samples obtained by 
kneading method were called HPMC KN and β-CD KN. 
Spray dryer systems 
The SD of BNZ with HPMC (1:1, w/w) and IC involving BNZ with β-
CD (1:1, molar ratio) were prepared using a mini Büchi B-191 Spray 
Dryer. BNZ, β-CD and HPMC were separately dissolved in a solution 
containing ethanol and water (2:1) at a minimum ratio necessary to 
solubilize them. The samples were obtained under the following 
conditions: inlet temperature at 140 °C, air flow at 5 ml/min and 
outlet temperature at about 80-110 °C. The samples were named 
HPMC SY and β-CD SY. 
Molecular modeling of BNZ-β-CD inclusion complex 
The geometry optimization of the BNZ-βCD and BNZ-βCD inclusion 
complexes were performed in vacuum and in the presence of 
water molecules using an MM2 force field as an implement in 
Hyper Chem (release 6.03 for windows). The presence of water 
was simulated by placing the solute molecules into a 25x25x25 Å 
box with approximately 200 water molecules and a minimum 
distance of 2.3 Å between the solute and water molecules. The 
most stable complex conformation was considered through the 
lowest interaction energy [15, 16]. 
Dissolution in vitro 
The dissolution of BNZ was performed with the isolated drug, the 
PM and samples obtained by EV, KN and SY. The dissolution test was 
performed using the paddle dissolution apparatus, at 37±5 ºC and 
75 rpms. For this analysis, the samples were weighed exactly 
equivalent to 50 mg of BNZ and transferred to vats containing 900 
ml of dissolution medium containing HCl 0.1 N with NaCl. A 4 ml 
sample was collected at predetermined intervals and immediately 
filtered (0.45 µm mesh). 
The volume removed from inside the vessel was immediately 
restored by the addition of a medium at 37±5 °C. To do a reading, 2 
ml of a dilution sample were collected from 10 ml of water. The BNZ 
concentration at each time interval was determined by UV 
spectrophotometry. Each sample was determined fourfold. 
The results were assessed based on the dissolution efficiency and 
were subsequently compared by analysis of variance (ANOVA) One 
Way, considering P<0.05. 
RESULTS AND DISCUSSION 
Molecular modeling of inclusion complexes 
For 1:1 stoichiometry in a vacuum, can appreciate important 
differences in the energies, and complexation by side large of the CD 
more favorable energetically however, the simulation in an aqueous 
solution had inverted values, and the complexes formed by the 
narrow portion of β-CD were the most favorable (table 1). 
Unlike the data obtained by the solubility diagram, the simulation of 
the formation of IC between BNZ and β-CD exhibits a more favorable 
stoichiometric complexation form 1:2 (drug: CD) in a vacuum. The 
values obtained in aqueous solution are equivalent to those obtained 
with 1:1 stoichiometry, in exactly the same way, so it is more likely 
that there simultaneously exists, in equilibrium, two stoichiometries 
in solution (table 2). 
 
Table 1: Enthalpy calculated for the formation of 1:1 stoichiometric complexes BNZ-βCD 
Included group  ΔH* (Kcal. mol-1) 
vacuum Aqueous medium 
imidazol-narrow 27.0 -2448.0 
benzyl-narrow 26.2 -2613.3 
benzyl-broad 10.9 -476.4 
imidazol-broad 10.9 -434.4 
* ΔH-enthalpy change 
 
Table 2: Enthalpy calculated for the formation of 1:2 stoichiometric BNZ-βCD complexes. 
Included group ΔH* (Kcal. mol-1) 
vacuum Aqueous medium 
broad-benzyl/imidazol-narrow -22.1 -2898.6 
narrow-benzyl/imidazol-broad -32.1 -2415.2 
broad-benzyl/imidazol-broad -16.2 -2813.9 
narrow-benzyl/imidazol-narrow -41.6 -2834.1 
* ΔH-enthalpy change 
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Experimental studies are needed to confirm these theoretical 
indications of complexity, among them spectra of nuclear magnetic 
resonance (NMR) are able to explain clearly the nature of inclusion 
complexes obtained in practice.  
fig. 2 show an illustrative example of the formation of IC in an 
aqueous state and fig. 3 and 4 show the spatial representation of all 
possible valued complexes. 
Dissolution in vitro  
The dissolution tests were performed in a total time of 60 min and, 
the dissolution curves shown, represent the profiles of the BNZ 
release rate percentage dissolved obtained for binary mixtures and 
pure BNZ versus time. 
In the dissolution curves of the PM, the SD and the IC, there was an 
increase in the BNZ dissolution rate when compared to the behavior 
of the drug alone. The dissolution rate of pure BNZ was slow: less 
than 10% of BNZ were dissolved in 1 hour, as fig. 5 shows. 
 
Fig. 2: BNZ-β-CD inclusion complex, 1:1 stoichiometrically 













Fig. 4: Possible stoichiometric structures of BNZ-βCD 1:2 by MM2 
Lima et al. 




Fig. 5: BNZ dissolution profile and the various binary systems 
(PM, SD and IC) 
 
According to this graph, comparing with pure BNZ, the speed and 
the dissolution rate of the drug in a PM with HPMC (HPMC PM) was 
higher, showing that, even without chemical interaction, just a 
mixture of poorly soluble drug with HPMC was able to improve the 
dissolution characteristics of BNZ. 
From the dissolution curves comparing the PMs with the SDs, all 
dispersions provided a major effect on the dissolution rate than the 
corresponding PM. Compared with pure BNZ, there was more speed 
in the release of drug in the evaporated dispersions (HPMC EV) than 
in those that were atomized (HPMC SY) and kneaded (HPMC KN). 
Thus, the rate of BNZ dissolution presents in the PMs and all the SDs 
with HPMC was significantly higher than BNZ alone. The 
improvement in dissolution rate relative to BNZ can be explained by 
the wetting effect of HPMC to BNZ. 
Regarding the β-CD IC, it becomes evident that all the complexes 
increased the BNZ dissolution rate and the complex obtained by 
evaporation (β-CD EV) had better results when compared to the 
kneaded (β-CD KN) and atomized (β-CD SD) complexes. The fact that 
the KN complexes achieved better results than the SY release is due 
to the processing of atomized samples, and these should be further 
optimized for observation of better results.  
An opposite result was obtained by Patil et al. (2014) [17], which 
described the highest drug release rate for lornoxicam from the 
spray dried ciclodextrin compared to those prepared by kneading 
and ultra sonification methods. Other recent works also highlight the 
increase in solubility of the drugs using β-CD [18-20].  
The increase in the dissolution rate seen for the IC with different 
drugs can be explained based on the higher solubility of amorphous 
state energy/reduction of crystallinity, the lower interfacial tension 
between the drug and water insoluble in CD-induced dissolution and 
higher solubility complex in water [21].  
The rapid dissolution of the drug in the first 5 min and the detection 
of more than 80% of BNZ dissolved in about 10 min, shows there 
was a BNZ complexation with β-CD. This behavior must be 
attributed to the high energy of the amorphous state and the 
formation of IC [22]. The PM also shows the corresponding 
improvement in solubility. 
Thus, according to the obtained data, rapid and excellent behavior in 
the formation of IC dissolution of the drug with β-CD is clearly 
demonstrated. Although SD with HPMC increased the rate of BNZ 
dissolution, it showed lower results than with the IC. 
Based on the dissolution profile dissolution efficiency at times 30 min 
(DE 30) and 60 min (DE 60) of each of the binary mixtures (table 3) 
were calculated. According to these figures, the dissolution of the drug 
dispersion with HPMC proved to be highly favored and, especially, in 
systems based on β-CD complexation relative to BNZ alone. 
 
Table 3: BNZ Dissolution Efficiency (DE) and binary mixtures at 30 and 60 min 
BNZ and binary mixtures % DE 30 min % DE 60 min 
β-CD EV 179,21% 89,60% 
β-CD KN 156,31% 78,15% 
β-CD PM 150,14% 70,07% 
β-CD SY 86,52% 43,26% 
HPMC EV 48,73% 24,36% 
HPMC SY 41,17% 20,58% 
HPMC KN 23,10% 11,55% 
HPMC PM 19,48% 9,74% 
BNZ 8,31% 4,15% 
 
The Analysis of Variance (ANOVA) revealed that with the level of 
significance of 5% when comparing the techniques of preparation of 
the samples (PM, KN, EV and SY) given, there is a greater statistical 
difference between these techniques when they form IC (Fcalculated: 
8.96; Ftabulated: 2.4) than in SD (Fcalculated: 4.7; Ftabulated: 2.4). 
This data enables us to say that to accommodate BNZ with β-CD, the 
choice between either preparation techniques will be of great 
relevance to ensure better solubility of the drug. Then, the statistical 
comparison was made between the two excipients (HPMC and β-
CD), using as constant preparation technique. 
Among all the treatments used in the KN mixtures, a higher 
difference (Fcalculated: 82.3; Ftabulated: 4.08) between the formation 
of SD with HPMC and β-CD IC confirms a better drug complex 
with CD solubility profile instead of mixing it with a polymer was 
shown. 
Similar results were observed for PM (Fcalculated: 82.21; Ftabulated: 4.08), 
showing an advantage for complexation. Whereas with the EV 
technique the differences were less dramatic but still significant 
(Fcalculated: 49.2; Ftabulated: 4.08). The lowest result was detected for SY 
(Fcalculated: 8.0; Ftabulated: 4.08), which denotes the smallest interference 
of this technique compared to the excipient of choice for BNZ. 
CONCLUSION 
In this study it was evident that the contribution of IC and SD 
systems, using three different techniques, increased the rate/speed 
of BNZ dissolution. The theoretical study of molecular modeling 
showed that BNZ can complex with β-CD in different ways, in an 
aqueous solution and in the presence of a vacuum so that, an 
excellent stoichiometric complexation can be brought about to 
improve BNZ solubility. 
The system of complexation of the drug with β-CD, represented by 
IC, proved to be more efficient when compared with their PM and 
the SD with HPMC, which guarantees a greater capacity for 
solubility/dissolution of the drug. The calculations regarding the DE 
at 30 and 60 min corroborate these findings. Considering the data 
obtained, it is possible to interpret the technique for the formation of 
β-CD IC as more effective in promoting the improvement of BNZ 
solubility when compared with obtaining a SD with HPMC which, in 
turn, may increase the bioavailability of the drug and improve its 
pharmaceutical potential. 
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